<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960711</url>
  </required_header>
  <id_info>
    <org_study_id>INT 85-13</org_study_id>
    <nct_id>NCT02960711</nct_id>
  </id_info>
  <brief_title>Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome</brief_title>
  <acronym>MeMeMe</acronym>
  <official_title>Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III randomized controlled trial on men and women with Metabolic syndrome (MetS) to test&#xD;
      the hypothesis that comprehensive life-style changes and/or metformin treatment prevent&#xD;
      age-related chronic non-communicable diseases (ArCD).&#xD;
&#xD;
      The aim of the present study is to evaluate the effect of a comprehensive life-style&#xD;
      intervention (including moderate physical activity and Mediterranean/macrobiotic diet with&#xD;
      moderate calorie and protein restriction), and of treatment with Metformin (a calorie&#xD;
      restriction mimetic drug) for the prevention of ArCD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III randomized controlled trial on men and women with MetS to test the hypothesis that&#xD;
      comprehensive life-style changes and/or metformin treatment prevent ArCD.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      2x2 factorial: 2,000 volunteers will be randomized in four equal groups of 500 each, and&#xD;
      allocated to the following treatments: METFORMIN (1700MG/DAY) + ACTIVE LIFESTYLE INTERVENTION&#xD;
      PLACEBO + ACTIVE LIFESTYLE INTERVENTION METFORMIN (1700 mg/day) alone PLACEBO alone The&#xD;
      metformin /placebo component of the study will be double blind.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total incidence of age related chronic diseases</measure>
    <time_frame>5 years</time_frame>
    <description>We will retrieve records for all Age related chronic diseases but we will first concentrate the analysis on cancer, coronary heart disease, stroke, and diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the intervention on total mortality and on the incidence of specific chronic diseases.</measure>
    <time_frame>8-10 years</time_frame>
    <description>The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group).&#xD;
The outcome measure describes multiple assessments with potentially different Units of Measure as indicated:&#xD;
Waist circumference: cm Glycemia: mg/dL Blood pressure: mmHg Total cholesterol, HDL cholesterol: mg/dL Triglycerides: mg/dL</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1600</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>METFORMIN (1700MG/DAY) + LIFESTYLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO+ LIFESTYLE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>METFORMIN (1700 mg/day) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: (two identical tablets) according to the blind assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]</intervention_name>
    <arm_group_label>METFORMIN (1700 mg/day) alone</arm_group_label>
    <arm_group_label>METFORMIN (1700MG/DAY) + LIFESTYLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ludipress, mg stereate, micronized hydrated silica, talcum</intervention_name>
    <description>Tablet</description>
    <arm_group_label>PLACEBO alone</arm_group_label>
    <arm_group_label>PLACEBO+ LIFESTYLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 55-74, waist circumference equal or greater than 85 cm for women and 100 cm for&#xD;
             men, plus at least two other factors among those defining the MetS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed diabetes (or baseline fasting glycemia above 7mmol/L at baseline&#xD;
             examination)&#xD;
&#xD;
          -  Cancer (except skin carcinoma) diagnosed in the last 5 years, or under treatment&#xD;
&#xD;
          -  Excessive frailty: in absence of agreed-upon measurements parameters and cutoff&#xD;
             points, the investigator will exclude subjects under the lower 5th percentile of the&#xD;
             muscular mass distribution estimated by impedance in previous studies&#xD;
&#xD;
          -  Conditions that contraindicate the use of MET because might favour lactic acidosis:&#xD;
&#xD;
               -  Renal, cardiac, hepatic, or respiratory insufficiency&#xD;
&#xD;
               -  Serum creatinine &lt;124Î¼mol/L, or proteinuria at baseline examination&#xD;
&#xD;
               -  Current treatment with K-sparing diuretics, or with proton pump inhibitors&#xD;
&#xD;
               -  Excessive alcohol consumption&#xD;
&#xD;
          -  Distressing side effects of MET treatment. Nausea and diarrhoea typically occur in&#xD;
             about one third of patients receiving MET for the first time at full dose. To avoid&#xD;
             dropouts for gastrointestinal discomfort we will treat all volunteers with half the&#xD;
             planned dose for one month in order to exclude intolerant subjects before&#xD;
             randomization. Participants randomized in the intervention group will continue to take&#xD;
             half a dose for one month and then shift to the full dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Berrino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS ISTITUTO NAZIONALE TUMORI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

